Modified-Two Tier Testing for the Serological Diagnosis of Lyme Disease: Past, Present and Future Clinical and Laboratory Implications

Wednesday, September 29, 3:30 - 4:30 p.m.
Exhibit Hall, Theater 1
Supported by DiaSorin, Inc.


Lyme Disease (LD) is the most common vector-borne disease in the US. Each year >30,000 cases of LD are reported to the CDC, but this is likely an underestimation. The standard two-tiered algorithm was introduced (1994) from the Second National Conference on Serologic Diagnosis of LD. In 2019 a shift occurred after many years of research demonstrating that using sequential screening assays could improve the detection of early Lyme Disease. This session will engage top experts with 75+ years of combined experience in LD to discuss MTTT, LD serological diagnosis, treatment, and the future directions.


After attending this session, participants will be able to:

  • Understand the history and paradigm shift from Standard Two-Tier Testing to Modified Two-Tier Testing for the serological diagnosis of Lyme Disease.
  • Understand future directions for Lyme Disease testing, diagnosis, and treatment.


Ashli Rode
Product Manager
DiaSorin, Inc.
Stillwater, MN


Raymond J. Dattwyler, MD
Professor of Microbiology/Immunology and Medicine
New York Medical College
Valhalla, NY

Thomas R. Fritsche, MD, PhD
Pathologist and Head, Section of Clinical Microbiology
Marshfield Laboratories
Marshfield, WI